Abstract
An increasing understanding of the immunopathogenesis of rheumatoid arthritis and advances in biotechnology have lead to the therapeutic application of immune-specific interventions. The complexity of this disorder has generated numerous investigations using a wide range of biologic interventions. This article presents the current and potential targets for such biopharmaceutical agents and discusses their utility in rheumatoid arthritis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 797-816 |
| Number of pages | 20 |
| Journal | Rheumatic Disease Clinics of North America |
| Volume | 21 |
| Issue number | 3 |
| State | Published - Jan 1 1995 |
| Externally published | Yes |
ASJC Scopus subject areas
- Rheumatology